Ipsen Boosts Rare Disease Portfolio with Blueprint’s BLU-782
By Pratika Pahwa
Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)
Published: 26 Oct-2019
DOI: 10.3833/pdr.v2019.i10.2467 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a quest to expand its rare disease pipeline, Clementia, a subsidiary of Ipsen, has entered into an agreement with Blueprint Medicines for up to US$535 M to develop BLU-782, an investigational ALK2 inhibitor for the treatment of fibrodysplasia ossificans progressiva (FOP)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS